Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects (NSERC partnered)

McGill University

$343,124.00

Multidimensional separation isolation and characterization of circulating tumour cells

EF 2012-13

Résumé
BACKGROUND. If cancer remains localized, it can often be treated, but if it metastasis, it vecome very difficult. Metastasis is thought to occur by so-called circulating tumor cells, or CTCs. These CTCs are emerging as a new element for prognosis of cancer, as well as for measuring the response to therapy, and to diagnose recurrence much earlier. The presence of as little as 3-5 CTCs per 7.5 ml of blood may have prognostic significance, this volume also contains ~ 100,000,000 white blood cells, rendering CTC isolation extremely challenging. In addition, CTCs are heterogeneous, and further it is important to differentiate between dead and live cells with metastatic potential. Although separation systems exist, they typically isolate cells based on a single property, either mechanical or biomolecular, and have been shown to miss many cells. PROJECT: Here we propose to develop a low cost CTC isolation cartridge that will capture cells from 10 ml of blood in a few minutes based on both mechanical and molecular characteristics. We thus hope to isolate a much greater variety of cells, and make CTCs a much more reliable diagnostic and prognostic tool. We believe that this will also help us understand which cells are responsible for cancer metastasis, which may then lead to targeted therapies to eradicate them. The low cost of our technology should also greatly accelerate the translation to the clinic and its adoption as a standard of care to help treat cancer patients.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
270385
Name
Juncker David
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Multidimensional separation isolation and characterization of circulating tumour cells
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$343,124
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Affinity-Based Purification; Antibody; Breast Cancer; Cell Size; Circulating Tumor Cell; Filtration; Hot Embossing; Microfabrication
Abstract
BACKGROUND. If cancer remains localized, it can often be treated, but if it metastasis, it vecome very difficult. Metastasis is thought to occur by so-called circulating tumor cells, or CTCs. These CTCs are emerging as a new element for prognosis of cancer, as well as for measuring the response to therapy, and to diagnose recurrence much earlier. The presence of as little as 3-5 CTCs per 7.5 ml of blood may have prognostic significance, this volume also contains ~ 100,000,000 white blood cells, rendering CTC isolation extremely challenging. In addition, CTCs are heterogeneous, and further it is important to differentiate between dead and live cells with metastatic potential. Although separation systems exist, they typically isolate cells based on a single property, either mechanical or biomolecular, and have been shown to miss many cells. PROJECT: Here we propose to develop a low cost CTC isolation cartridge that will capture cells from 10 ml of blood in a few minutes based on both mechanical and molecular characteristics. We thus hope to isolate a much greater variety of cells, and make CTCs a much more reliable diagnostic and prognostic tool. We believe that this will also help us understand which cells are responsible for cancer metastasis, which may then lead to targeted therapies to eradicate them. The low cost of our technology should also greatly accelerate the translation to the clinic and its adoption as a standard of care to help treat cancer patients.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Juncker, David; Mihalcioiu, Catalin; Omeroglu, ATILLA; Veres, Teodor
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $343,124~ $0~